Results 71 to 80 of about 334,470 (291)
Much new evidence on oral anticoagulation has come to light in recent years. Non-vitamin-K-dependent oral anti- coagulants (NOAC) have been developed and have been introduced into clinical practice. In this review, we present the current state of the evidence on anticoagulation for various indications with vitamin K antagonists (VKA) and with NOAC.This
Ertunc, Altiok, Nikolaus, Marx
openaire +2 more sources
Impact of anticoagulation prior to COVID-19 infection: a propensity score–matched cohort study
Tremblay and colleagues asked whether patients receiving either routine anticoagulation or antiplatelet therapy for existing conditions prior to becoming ill with COVID-19 have different outcomes from patients receiving neither therapy.
D. Tremblay +18 more
semanticscholar +1 more source
There is a paucity of data on management strategies and clinical outcomes after recurrent venous thromboembolism (VTE). In a multicenter registry enrolling 3027 patients with acute symptomatic VTE, the current study population was divided into the ...
Yugo Yamashita +22 more
doaj +1 more source
Background: The international normalized ratio (INR) is designed to monitor vitamin K antagonist (VKA) treatment. Before patients start a self-managing VKA program, parallel measurements are conducted to compare point-of-care testing (POCT) INR with ...
Nikolaj Julian Skrøder Nytofte +1 more
doaj +1 more source
Background and purpose A subset of ischaemic stroke patients with atrial fibrillation (AF) have ischaemic stroke despite anticoagulation. We sought to determine the association between prestroke anticoagulant therapy and recurrent ischaemic events and ...
S. Yaghi +31 more
semanticscholar +1 more source
Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum
Two specific reversal agents for direct oral anticoagulants (DOACs) have been approved in the United States: idarucizumab for dabigatran reversal and andexanet alfa for apixaban and rivaroxaban reversal.
A. Cuker +7 more
semanticscholar +1 more source
Background The clinical impact of different prophylactic anticoagulation regimens among hospitalized patients with coronavirus disease 2019 (COVID-19) remains unclear.
L. Ortega‐Paz +11 more
semanticscholar +1 more source
Trends in Venous Thromboembolism Anticoagulation in Patients Hospitalized With COVID-19
Key Points Question What is the frequency with which patients hospitalized with COVID-19 are treated with venous thromboembolism (VTE) prophylactic- and treatment-dose anticoagulation, and what is the association of anticoagulation with in-hospital and ...
Valerie M. Vaughn +8 more
semanticscholar +1 more source
Most patients on chronic oral anticoagulant therapy are monitored through anticoagulation clinics, or rather by assistant physicians. Our aim was to compare warfarin anticoagulated patients who were treated with usual medical care (assistant physician ...
Rui Barreira +6 more
doaj +1 more source
Background: Oral anticoagulants (OACs) are essential for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF). However, the appropriateness of anticoagulation treatment in locally practice remains unclear.
Xiao-Yuan Zheng +9 more
doaj +1 more source

